Stock fact sheet · data as of
Harrow Health, Inc. (HROW): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative / Distressed
Is HROW undervalued?
At 28.75 (close of 16 Oct 2026), HROW trades 480% over the GLS average fair value of 4.96, with 0 of 1 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
Only 1 of the nine models produced a value (10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files HROW under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for HROW
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 4.96 | -83% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -3.62 | -113% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 66.50 | +131% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: HROW passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 3.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -1.7%, ROE -9.8%, ROA -1.3% - with debt at 4.80 times equity and a free-cash-flow yield of 0.5%. Debt of 4.80 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.
Harrow Health, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product Sales Net 100%, Other Revenues 0% (quarter Q2 FY2026).
Institutional ownership scores 7/10, insider activity 2/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -1.7% |
|---|---|---|---|
| GLS Moat | 3.7 / 10 | ROE | -9.8% |
| Debt / equity | 4.80 | ROA | -1.3% |
| Free-cash-flow yield | 0.5% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 2 · 5 / 10 |
Wheel Score 42: Weak
HROW scores 42 out of 100 on the Wheel Score, in the Weak band (under 50). Value 0/25, Health 9/20, Moat 6/15, Premium 15/20, Stability 13/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 80% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (15 of 20) because volatility this high usually comes with a reason. The option chain is deep: 56,200 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 583k shares a day on a market cap of $1.1B, with a beta of 0.24 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 13 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -480% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 6 / 15 | moat 3.7/10 | |
| Premium | 15 / 20 | implied volatility 80% | |
| Stability | 13 / 20 | 583k shares/day, $1.1B cap, beta 0.24 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 9 Nov 2026 (after the close), 24 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Harrow Health, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals, Inc. | 26.42 | 45.40 | +42% | 77Good | $1.1B |
| CRON Cronos Group Inc. | 3.20 | 2.96 | -8% | 58Fair | $1.2B |
| PCRX Pacira BioSciences, Inc. | 36.40 | 39.44 | +8% | 63Fair | $1.5B |
| ETON Eton Pharmaceuticals, Inc. | 51.33 | 15.29 | -236% | 52Fair | $1.5B |
| COLL Collegium Pharmaceutical, Inc. | 23.18 | 147.77 | +84% | 74Good | $755M |
| PAHC Phibro Animal Health Corporation | 37.93 | 43.87 | +14% | 72Good | $1.5B |
| ANIP ANI Pharmaceuticals, Inc. | 72.28 | 243.25 | +70% | 77Good | $1.7B |
| TRLV Trulieve Cannabis Corp. | 9.97 | 27.65 | +64% | 45Weak | $1.7B |
| IRWD Ironwood Pharmaceuticals, Inc. | 3.77 | 12.28 | +69% | 69Good | $623M |
| ALVO Alvotech | 5.31 | - | - | 33No options | $1.9B |
| PRGO Perrigo Company plc | 15.95 | 37.60 | +58% | 45Weak | $2.2B |
| AQST Aquestive Therapeutics, Inc. | 4.06 | - | - | 45Weak | $510M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about HROW
Is HROW undervalued right now?
No: at 28.75 the stock trades 480% above the GLS average fair value of 4.96 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of HROW and what does it mean?
HROW scores 42 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for HROW?
4.96 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Harrow Health, Inc. report earnings next?
The next earnings report is due on 9 Nov 2026 (after the close), 24 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does HROW have listed options, and how liquid are they?
Yes. The nightly snapshot found 452 listed contracts with 56,200 open interest across all expiries and implied volatility of 80% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.